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SPECIAL E D I T O R I A L 
A N N O U N C E M E N T 
Cadaveric Renal Transplantation with Cyclosporine: 
Experiences in 148 Patients at a Single Institution 
W. Land, L. A. Castro, K. Günther, C. Hammer, C. Hillebrand, W.-D. Miner, N. Schmeller, 
B. Schneider, W. Siebert, R. A. Zink, and H. Zöttlein 
SINCE NOVEMBER 1980, 195 renal transplantations have been performed at 
our center using cyclosporine as a new immu-
nosuppressive agent. Twenty-five patients 
were treated with cyclosporine as the sole 
immunosuppressive agent in the European 
Multicentre Trial. 1 Outside a control study, 
cyclosporine, in combination with small doses 
of methylprednisolone, was used in 157 cadav-
eric renal transplantations as well as in 5 
living related donor transplantations. Cyclo-
sporine, in combination with steroids, was 
used in 8 combined renal and pancreatic 
transplantations. This article reports our 
experiences with 148 cadaveric renal trans-
plantations performed by March 1983, using 
cyclosporine in combination with steroids as 
basic immunosuppressive therapy. 
MATERIALS AND METHODS 
Patient Population 
This study includes 140 consecutive transplants of 
cadaveric renal allografts performed between March 
1982 and March 1983 on recipients aged 9-61 years. No 
patients were excluded from cyclosporine treatment, 
neither patients with known liver disease nor patients with 
primarily nonfunctioning kidneys without immediate 
diuresis. Of the 140 patients, 115 got a primary renal 
allograft and 25 received a secondary or tertiary allograft. 
All recipients had received at least 3 random type-specific 
blood transfusions prior to transplant. Eight patients 
(aged 25-49 years) suffering from Type I diabetes melli-
tus and end-stage renal disease received combined renal 
and pancreatic allografts. 
Immunosuppressive Protocol 
Basic immunosuppression. Cyclosporine was admin-
istered intravenously before the operation and on day 1 
postoperatively in a dose of 4 mg/kg of body weight and 
continued by oral administration in a dose of 15 mg/kg 
for 1 month after transplantation, when it was decreased 
by 2 mg/kg monthly to a maintenance level of 6-7 
mg/kg. Methylprednisolone was begun at 8 mg daily 
immediately after the operation and maintained at that 
level. 
Antirejection treatments. Antirejection treatment 
consisted of 3 i.v. bolus injections of 500 mg methylpred-
nisolone during the first rejection episode. The second and 
third rejection episodes were treated by administration of 
A L G / A T G over a period of 7 days, in combination with 
methylprednisolone in a dose of 125 mg i.v. daily until 
reversal. 
"Triple" immunosuppressive therapy. In recipients 
of a secondary or tertiary renal allograft and in patients 
with preformed antibodies higher than 50%, cyclosporine, 
azathioprine, and methylprednisolone were administered 
during the first week posttransplant as follows: cyclospo-
rine was given as described above; azathioprine in a dose 
of 2 mg/kg initially, then decreased to 1 mg/kg; methyl-
prednisolone (i.v.) in a dose of 500 mg daily, tapering to 
30 mg daily. 
From the second week after transplantation, the origi-
nal basic immunosuppressive treatment was continued. 
Antirejection treatment was applied as described above. 
Combined Renal and Pancreatic 
Transplantation 
Pancreas transplantation was performed using the 
technique of segmental pancreatic allografting by occlud-
ing the duct system with Ethibloc. Postoperative manage-
ment consisted of cyclosporine administration in combi-
nation with steroids; in addition, administration of hepa-
rine, antibiotics, and Somatostatine. 
Incidence of Infections Under Cyclosporine 
Therapy 
The incidence of infections described in this report 
concerns only the manifestation of severe infections 
requiring hospitalization of the transplant patient. In 
addition to careful clinical assessment and appropriate 
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microbiologic tests for evidence of infectious diseases, 
detailed laboratory investigations were carried out when-
ever an overt virus disease was suspected. 
Fine-Needle Aspiration Cytology 
The methodology used has been described elsewhere.2 
In brief, fine-needle aspiration has to be done under 
sterile conditions by placing a spinal needle into the cortex 
of the graft. The aspirated material was dispersed into a 
centrifuge vial by means of 5 ml RPMI medium held in 
the suction syringe. 
The mouse monoclonal antibodies used were directed 
against pan-T lymphocytes (OKT3) , helper-inducer T 
lymphocytes (OKT4) , and cytotoxic/suppressor T lym-
phocytes (OKT8) . 
RESULTS 
Cadaveric Renal Transplantation 
The overall graft survival rate (graft sur-
vival probability as calculated by the Cutler-
Ederer test) after primary cadaveric renal 
transplantations in 115 consecutively treated 
patients under cyclosporine-methylpredniso-
lone therapy is depicted in Fig. 1; the result in 
the historical control group (steroids + aza-
thioprine; TV = 150) is shown for comparison. 
At 1 year, the graft survival probability is 70% 
in the cyclosporine group compared to 50% in 
the control group. The difference of 20% is 
statistically significant. The overall graft sur-
vival rate after secondary or tertiary cadaveric 
renal transplantation in 25 patients under 
cyclosporine-methylprednisolone therapy is 
depicted in Fig. 2. The 1-year graft survival 
probability of 70% is identical to that obtained 
in the primary renal allograft group, although 
during the first 6 months after transplantation 
there was a slightly higher incidence of graft 
losses. Of these 25 patients, 18 were treated 
during the first week following transplanta-
tion by using the "triple" immunosuppressive 
protocol (see below). 
Of the original 115 patients treated with 
cyclosporine after primary renal transplanta-
tion, 111 are currently alive. Of the 4 patients 
who died, 2 did so with functioning grafts, 1 
from spontaneous intracerebral hemorrhage 
at 1 month and the other from acute cardiac 
failure at 6 months. One patient with a pri-
mary nonfunctioning kidney ( A T N ) died 
C3 3 6 9 MON12 
Fig. 1. Graft survival rates in primary renal trans-
plantation, comparing cyclosporine-methylprednisolone 
treatment (CsA) vs. historical controls (azathioprine-
steroids treatment). 
from acute cardiac failure at 1 week, another 
patient from sepsis at 6 months. There was an 
immunologic cause of graft loss only in 14 
patients, and a nonimmunologic cause of graft 
loss in 3. Al l the original 25 patients treated 
with cyclosporine after retransplantation are 
alive. There was an immunologic cause of 
graft loss in 6 patients and a nonimmunologic 
cause of graft loss in 1. 
"Triple" Immunosuppression in 
Immunologically High-Risk Patients 
As described in Materials and Methods, 26 
immunologically high-risk patients (18 re-
transplantations and 8 recipients with pre-
formed antibodies > 50%) were treated with 
cyclosporine, azathioprine, and steroids dur-
ing the first week after transplantation. The 
result of this pilot study is depicted in Fig. 3. 
We observed a 1-year graft survival probabil-
ity of 70%. Remarkably, all irreversible graft 
rejections occurred during the first 3 months 
after transplantation. In none of these 26 
patients treated initially with the "triple" 
immunosuppressive regimen has either severe 
infection or malignancy been seen so far. 
Combined Renal and Segmental Pancreatic 
Transplantation 
The results obtained with this kind of surgi-
cal treatment in Type 1 diabetics with end-
stage renal disease are listed in Table 1. 
Although our experience with cyclosporine 
therapy in combined renal and pancreatic 
transplantation is limited to 8 cases, the 
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Fig. 2. Graft survival rates in pri- LL 
mary renal transplantation (/V =115) ^ 
compared to retransplantat ion 9£ 
(/V - 25). W 
results obtained with this new immunosup-
pressive agent are encouraging and promis-
ing. 
Incidence of Infectious Diseases Under 
Cyclosporine Treatment 
The incidence of clinically manifested 
severe infections that required hospitalization 
is listed in Table 2. Of the original 140 
patients treated with cyclosporine after cadav-
eric renal transplantation, only 13 (9%) were 
hospitalized with a bacterial infection (1 
death due to sepsis), 9 (6%) with a viral 
infection, and 2 (1.3%) with a fungal infec-
tion. 
Immunologic Monitoring: Fine-Needle 
Aspiration Cytology 
Due to the difficulty in detecting acute 
rejections in patients treated with cyclospo-
n=26 
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Fig. 3. Graft survival rate in immunologically high-
risk patients treated with cyclosporine, azathioprine, 
and methylprednisolone during the first week following 
transplantation. 
rine, recourse was made to fine-needle aspira-
tion cytology. The method allows not only 
estimation of onset, severity, and course of 
rejection but also measurement of the impact 
of treatment and differentiation between 
cyclosporine side effects, acute tubular necro-
sis, and acute cellular rejection. Differentia-
tion of the inflammatory cell populations by 
monoclonal antibodies has proved that with 
increasing severity of rejection, high numbers 
of lymphocytes of the cytotoxic/suppressor 
cell compartment invade the graft. Helper 
cells therefore decrease relatively in terms of 
percent (Fig. 4). 
This observation of a high influx of cyto-
toxic cells into the graft during rejection was 
not changed after introduction of cyclosporine 
as the immunosuppressant. Despite its power-
ful effect on graft rejection, no change in 
lymphocyte numbers in the peripheral blood 
could be seen. During rejection under cyclo-
Table 1. Results of Combined Pancreatic and Renal 
Transplantation in 8 Patients Treated with 
Cyclosporine and Steroids* 
Patients alive 7 
Function of both grafts 5-f 
Function of the renal graft (2 years) 1 
Rejection of both grafts (1 month) 1 
Death {acute liver failure) 1 
*At the Transplantation Center, Munich, 1 9 7 9 - 1 9 8 3 ; 
N = 12 /11 . 
f 2 years, 1 year, 5 months, 4 months, and 3 months, 
respectively. 
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Table 2. Incidence of Infectious Diseases in 140 Cyclosporine-Methylprednisolone-Treated Patients 
No. of 
Patients 
(N = 1 3 / 1 4 0 ) 
Bacterial Infections 
Manifestation Associated with A R T * Outcome 
9 UTI, prostatitis, pyelonephritis No Recovery 
1 Graft infection at biopsy Yes Transplantectomy 
1 Otitis media No Recovery 
1 Endocarditis No Recovery 
1 Pneumonia, sepsis No Death 
No. of 
Patients 
(N = 9/140) 
Viral Infections 
Outcome Manifestation Pathogen ART 
5 Interstitial pneumonia: cerebral signs, general C M V Yes (3) Recovery 
symptoms No (2) 
2 Herpes genitalis, Herpes simplex (generalized) Herpes virus Yes(1 ) Recovery 
No(1) 
2 Fever, pneumonia Unknown No Recovery 
No. of 
Patient«? 
Fungal Infections 
Outcome (N = 2/140) Manifestation Pathogen A R T 
1 Tracheitis Candida albicans No Recovery 
1 Sepsis, UTI Candida albicans Yes Recovery with 
graft loss 
• A R T : Antirejection therapy. 
n 
30 I-
25 
20 
15 
10 
KORRELATION OKT 3 / OKT 8 
T / T 8 C 
I I O K T 3 
g = l OKT 8 
n-51 
AR 0 
n-43 
AR I 
n-42 
AR II 
n-12 
AR III 
Fig. 4. OKT8 + cells increase in the graft with 
increasing severity of the rejection reaction. 
sporine therapy, lymphocyte numbers in-
creased in the graft, but less than with conven-
tional therapy. Surprisingly enough, no 
impact on helper cells was seen under cyclos-
porine therapy. A new aspect was analyzed 
(Table 3) when conversion of numbers of 
helper and cytotoxic suppressor cells was mea-
sured in the peripheral blood and in the graft. 
High numbers of lymphocytes in the periph-
ery and the graft, preferably belonging to the 
Table 3. Behavior of Peripheral Granular Lymphocytes 
and T4/T8t Cells in Rejection Episodes vs. 
Viral Infections 
Rejection 
Episode 0 
Rejection 
Episode 2 
Virus 
Infection 
Lymphocytes in 
fine-needle biopsy 
Lymphocytes in 
peripheral blood 
OKT3 
OKT4 
OKT8 
OKT4 /OKT8 ratio 
In peripheral 
blood 
8.5 23 .9 31.7 
7.7 6.3 18.3 
9.8 18.3 29.2 
4.8 8.2 4.5 
4.9 13.3 25.6 
1.2 0.7 0.2 
2.6 2.4 0.45 
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T8 compartment, heralded in virus infection. 
The ratio of T4 to T 8 + cells was below 0.5 in 
aspirate and peripheral blood. 
A further sign distinguishing virus infection 
from acute rejection seems to be the number 
of large granular lymphocytes—supposedly 
responsible for the natural killer activity. Dur-
ing acute rejection, peripheral blood lacks 
large granular lymphocytes. In the graft, 
large granular lymphocytes reach up to 12% 
of the inflammatory cell compartment. Dur-
ing virus infection, however, large granular 
lymphocytes increase in the peripheral blood 
and the graft to values up to 25%, with the 
mean of 14, i.e., 10%. 
DISCUSSION 
The results reported confirm the potential 
usefulness of cyclosporine in combination with 
low doses of steroids to improve the graft 
survival in cadaveric renal transplantation 
with an extremely low incidence of morbidity 
and mortality. Compared with the historical 
controls treated with conventional therapy at 
our center, a 20% difference in the results 
obtained with the use of cyclosporine was 
observed. Interestingly enough, the 70% 1-
year graft survival probability under cyclo-
sporine-methylprednisolone therapy was ob-
served in primary renal transplantation as 
well as in retransplantation. By using a short-
term "triple" immunosuppressive regimen 
(cyclosporine, azathioprine, methylpredniso-
lone) immediately after surgery, a 70% 1-year 
graft survival rate of cadaveric renal allo-
grafts could also be achieved in immunologi-
cally high-risk patients. Although these 
results are similar to those reported by oth-
ers,3"6 one has to be careful in interpreting the 
current improved graft survival rates as defi-
nite long-term results. Thus, within l/ 2 year the 
6-month graft survival rate of 90% came down 
to the 12-month graft survival rate of 70% at 
our own institution. Nevertheless, when evalu-
ating the results at our institution, one has to 
take into account that no exclusion criteria for 
the use of cyclosporine were applied, as had 
been done in the European Multicentre Trial. 
This circumstance represents one of several 
difficulties in comparing the efficacy of the 
combined cyclosporine treatment with that of 
cyclosporine monotherapy. 
As far as the results in immunologically 
high-risk patients are concerned, a valid con-
clusion cannot be drawn from the data 
obtained at the present time. Nevertheless, 
two aspects seem worthwhile to discuss: (1) 
Our first clinical impression of a strong immu-
nosuppressive potency of the "triple" regimen 
used is confirmed by experimental studies 
showing a synergistic immunosuppressive 
effect of cyclosporine and azathioprine in 
three different animal allograft models.7 (2) 
According to our observations (no incidence 
of severe infection or malignancy), such a 
combined immunosuppressive therapy seems 
to be safe for the patient, provided all three 
drugs are administered only for a short period 
of time. 
Apart from the improved results in graft 
survival rates, the decreased morbidity, par-
ticularly in terms of decreased infectious dis-
eases, is one of the remarkable advantages of 
cyclosporine treatment. Infections remain an 
important and typical complication of renal 
transplantation, which often has led to graft 
loss or patient death. Therefore, the decreased 
incidence of severe infectious diseases (of bac-
terial, viral, or fungal origin) as observed by 
us and others3 , 8 is tremendously encouraging. 
In this context, it remains to be studied in the 
future why particularly the incidence of viral 
infections is lower than expected in light of the 
mode of action of cyclosporine. Despite all the 
advantages, there is, however, one serious 
disadvantage in the use of cyclosporine: It 
makes the early detection of rejection episodes 
a difficult procedure, especially in patients 
with primarily nonfunctioning kidneys. A lot 
of "classical" rejection symptoms have com-
pletely (or partially) disappeared and are no 
longer seen by clinicians. This obvious diffi-
culty with cyclosporine use has given rise to a 
search for new and better methods for immu-
nologic monitoring. One of us (C. H.) tried to 
use P. Häyry's fine-needle aspiration cytology 
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as a method helpful for the accurate detection 
of rejection episodes. Although this method is 
not fully convincing from the practical point 
of view at the present time, some conclusions 
can be drawn: Fine-needle biopsy, in combina-
tion with highly specific monoclonal antibod-
ies, provides some important new information 
about the background of high-lymphocytic 
inflammation. Clinical statements like onset, 
severity, and progress of an acute rejection 
given by the aspiration cytology can be con-
firmed and precised with this method in cer-
tain circumstances. A possible new prominent 
example is to differentiate between acute 
rejection and virus infection with the help of 
monoclonal antibodies and by differentiating 
large granular lymphocytes from other cell 
populations. With this information, unneces-
sary and dangerous immunosuppressive ther-
apy in cases of nondiagnosed viral infections 
might be avoided. 
Parallel to the improvement of the results in 
cadaveric renal transplantation under cyclo-
sporine therapy, the results of combined renal 
and pancreatic transplantation have im-
proved, although the number of patients 
treated with this surgical method at our insti-
tution is too small to draw any valid conclu-
sion. Nevertheless, in view of the current 
uncertain state of the art relating to the 
technique of pancreatic grafting, the intro-
duction of cyclosporine in the clinical pan-
creatic allografting program seems to improve 
the results in this field of organ transplanta-
tion slightly but steadily. 
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